SEATTLE, WA--(Marketwired - Nov 25, 2014) - Atossa Genetics Inc. (
About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com .
About The Stock & Bond Club of South Florida
The Stock and Bond Club of South Florida is a leading association of financial and investment professionals in South Florida. Its mission is to serve the profession by advocating best practices within the securities industry, while enhancing members' business and professional skills. Monthly meetings are sponsored by highly regarded public companies seeking to share their story with qualified members of the financial community -- including advisors, planners, brokers, analysts, and the media. For more information please visit their website at: http://sbcsf.com
About the National Investment Banking Association (NIBA)
Since 1982, the National Investment Banking Association (NIBA) has been a not-for-profit association for national, regional and independent broker dealers, investment banking firms, investment advisors, and related capital market service providers. NIBA has over 30 years of experience hosting conferences featuring public and private micro-cap and small-cap companies. The NIBA Membership represents over 60+ services centered around micro-cap and small-cap companies. For more information please visit www.nibanet.org .
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com .
Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
